Medical/Pharmaceuticals

Medit and OraQ Announce Strategic Partnership to Advance AI-Driven Intelligence in Digital Dentistry

Collaboration unites two leaders in innovation to redefine how clinical insight is delivered across the dental ecosystem NEWPORT BEACH, Calif., Nov. 12, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning solutions, and OraQ, a pioneer in AI-powered clinical intelligence, today ...

2025-11-12 21:00 1147

EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A

TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...

2025-11-12 20:47 1396

CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025

CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination withGLP-1 RAs. ATLANTA, Nov. 11, 2025 /PRNewswire/ -- CureGene Pharmaceuticals ("CureGene") today announced the first discl...

2025-11-12 06:24 2041

Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring

SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...

2025-11-11 22:00 1276

From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care

BANGKOK, Nov. 11, 2025 /PRNewswire/ -- Aura Bangkok Clinic, a leader in Thailand's medical aesthetic industry, is enhancing the country's reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training p...

2025-11-11 22:00 1170

Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market

SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...

2025-11-11 22:00 1273

Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION

- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier - UGAP (France's central public procurement agency) registration completed, opening opportunities withFrance's largest public hospitals SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft

2025-11-11 21:00 1050

MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics

CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...

2025-11-11 17:40 1100

Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"

* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...

2025-11-10 21:00 1389

Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo

BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...

2025-11-10 20:30 1079

Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells(Treg)-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...

2025-11-10 20:06 1177

LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences  ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in aglobal Phase 2 clinical trial of LB-P8, a novel therapeutic candidate for Primary Sclerosing Ch...

2025-11-10 20:00 968

Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer

HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...

2025-11-10 19:39 1042

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...

2025-11-08 18:00 1395

Lunit AI Maps the Tumor-Immune Landscape to Predict Immunotherapy Response and Discover New Antibody Targets at SITC 2025

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precis...

2025-11-07 22:05 2969

HanchorBio Presents Two Late-Breaking Abstracts at the Society for Immunotherapy of Cancer 2025 Demonstrating Best-in-Class Potential of HCB101 in Advanced Cancers

Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a ...

2025-11-07 22:00 2776

Coreline Soft Unveils AVIEW 2.0 at RSNA 2025: Next-Generation AI Platform Redefining Radiology Workflow Standards

CHICAGO and SEOUL, South Korea, Nov. 7, 2025 /PRNewswire/ -- Coreline Soft  will introduce its groundbreaking chest AI platform AVIEW 2.0 at RSNA 2025 (November 30–December 4, Chicago), demonstrating how unified AI automation is fundamentally trans...

2025-11-07 21:00 1511

Alebund Presents Phase 3 Trial Results of AP301 at the American Society of Nephrology (ASN) 2025 Congress

* Clinically and statistically significant superiority of AP301 maintenance dose versus ineffective low dose in reducing serum phosphate levels was established and AP301's efficacy is sustained throughout the 52 weeks of treatment. * The non-inferiority of AP301 to sevelamer carbonate in redu...

2025-11-07 20:00 1310

Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, andEvinova, a global ...

2025-11-07 14:00 1536

Volpara Now Operates Under Lunit Brand, Advancing a Unified Vision for AI Cancer Intelligence

The rebranding marks the first phase of Lunit's unified global identity, connecting breast health, AI detection, and precision oncology under one name. SEOUL, South Korea, Nov. 6, 2025 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and therapeutics, today ann...

2025-11-07 08:14 1169
1 ... 9101112131415 ... 250